Myriad Genetics

Myriad Genetics
Name	Myriad Genetics
Type	Public
Industry	Biotechnology
Founded	1991
Founders	Mark Skolnick, Peter Meldrum
Headquarters	Salt Lake City, Utah
Products	BRACAnalysis, hereditary cancer tests, pharmacogenomic tests

Myriad Genetics is a biotechnology company focused on genetic testing for hereditary diseases and pharmacogenomics, founded in 1991 with operations centered in Salt Lake City and research ties to academic institutions. The company developed widely used diagnostic tests that intersect with clinical practice in oncology, genetics, and precision medicine, and it has been involved in prominent legal cases, partnerships, and controversies involving patents, regulatory policy, and patient access.

History

Myriad Genetics was established by researchers from the University of Utah and collaborators linked to institutions such as Harvard University and Stanford University; early leadership included scientists who participated in projects associated with the Human Genome Project and innovators in molecular diagnostics and biotechnology entrepreneurship. In the 1990s and 2000s the company expanded through commercialization of tests developed from academic research, collaborations with hospitals like Mayo Clinic and networks including Kaiser Permanente, and strategic moves involving initial public offerings and dealings with investment firms such as Goldman Sachs and JPMorgan Chase. During its evolution Myriad engaged with regulatory agencies including the United States Food and Drug Administration and policy discussions in the United States Congress, while also responding to changing reimbursement landscapes influenced by payers such as Centers for Medicare & Medicaid Services and private insurers like Blue Cross Blue Shield. Corporate milestones included leadership transitions involving executives with prior roles at firms connected to Genentech and Roche, acquisitions and divestitures tied to companies such as Assurex Health and partnerships with genetic reference labs like Invitae and Quest Diagnostics.

Business operations and products

Myriad's core business has centered on hereditary cancer testing services, marketed under brand names including BRACAnalysis for BRCA1 and BRCA2 mutations, alongside multi-gene panels covering genes like PALB2, CHEK2, and TP53 used in risk assessment for breast, ovarian, and other cancers. The company diversified into companion diagnostics, pharmacogenomic assays linked to drug development collaborations with pharmaceutical companies such as Pfizer, AstraZeneca, and Merck & Co., and commercial offerings aimed at population screening and oncology decision support used by clinical centers at institutions like Memorial Sloan Kettering Cancer Center and Johns Hopkins Medicine. Myriad operated laboratory facilities complying with standards from accreditation bodies such as College of American Pathologists and regulatory frameworks like Clinical Laboratory Improvement Amendments while negotiating contracts with hospital systems, academic medical centers, and national networks including UnitedHealthcare and Cigna. The company offered software and interpretive services that interfaced with electronic health record systems developed by vendors like Epic Systems and Cerner Corporation and collaborated with research consortia including The Cancer Genome Atlas and ClinGen.

Legal and patent controversies

Myriad was central to landmark litigation over the patentability of human genes, litigating cases that reached the Supreme Court of the United States resulting in rulings that addressed patent law under precedents such as Diamond v. Chakrabarty and statutory interpretation of 35 U.S.C. § 101. The company's enforcement of patents on BRCA1 and BRCA2 sequences prompted challenges from advocacy groups like ACLU and public interest organizations including American Association for Cancer Research and research institutions such as Cancer Research UK. International disputes involved patent offices and courts in jurisdictions including European Patent Office, Australia, and Canada, and generated policy responses from bodies like the World Health Organization and national health ministries. Litigation and public debate also intersected with payers, biotech competitors such as Ambry Genetics and GeneDX, and regulatory agencies that influenced gene testing access, clinical trials, and licensing practices.

Clinical and scientific contributions

Myriad contributed data and analytical methods to the clinical interpretation of variants through participation in variant databases and collaborations with academic centers like Stanford Health Care and networks including Global Alliance for Genomics and Health; its research influenced guidelines developed by professional societies such as the American Society of Clinical Oncology and the National Comprehensive Cancer Network. The company published studies in peer-reviewed journals alongside investigators from institutions like Dana-Farber Cancer Institute and University of California, San Francisco on genotype-phenotype correlations, variant classification frameworks aligned with guidance from the American College of Medical Genetics and Genomics, and outcomes research tied to hereditary cancer management strategies practiced at centers like Cleveland Clinic and MD Anderson Cancer Center. Myriad’s laboratory methods contributed to clinical workflows for risk-reducing interventions including surgeries performed by surgeons associated with Memorial Sloan Kettering Cancer Center and chemoprevention trials sponsored by cancer research organizations.

Financial performance and corporate governance

As a publicly traded company listed on exchanges governed by rules from entities such as the Securities and Exchange Commission, Myriad’s financial results reflected revenue streams from diagnostic testing, licensing agreements, and collaborations with pharmaceutical firms; financial reporting involved audits by major accounting firms and investor communications to stakeholders including institutional investors such as Vanguard Group and BlackRock. The company’s governance included a board with directors experienced in biotechnology, finance, and healthcare policy, interacting with proxy advisory firms like Institutional Shareholder Services and regulatory compliance frameworks that consider statutes such as the Sarbanes-Oxley Act. Strategic shifts in revenue mix and cost structure were influenced by reimbursement decisions from payers including Medicaid programs and commercial insurers, market competition from laboratories like Laboratory Corporation of America and BioReference Laboratories, and capital markets activity during mergers, acquisitions, and equity financing events.

Criticism and ethical issues

Criticism of Myriad focused on the ethics of proprietary control over genetic information, patient access raised by advocacy groups including Breastcancer.org and National Coalition for Cancer Survivorship, and debates about data sharing urged by consortia such as Global Alliance for Genomics and Health and nonprofit organizations like Genetic Alliance. Bioethical concerns involved informed consent processes evaluated by institutional review boards at universities such as Yale University and policy discussions involving legislators in the United States Congress; commentators from think tanks like the Brookings Institution and The Hastings Center scrutinized implications for equity and innovation. Privacy advocates referenced statutes and frameworks including Health Insurance Portability and Accountability Act and international instruments such as the General Data Protection Regulation in discussions of genomic data stewardship, while researchers and clinicians debated responsibilities for variant reclassification, disclosure, and implications for family members treated at hospitals like Boston Children's Hospital and St. Jude Children's Research Hospital.

Category:Biotechnology companies